AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The transcription factor CCAAT/enhancer binding protein alpha, or C/EBPalpha, encoded by the CEBPA gene, is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and Cebpa knockout mice exhibit an early block in maturation. Dominant-negative mutations of CEBPA have been found in some patients with acute myeloid leukemia (AML), but not in AML with the t(8;21) translocation which gives rise to the fusion gene RUNX1-CBF2T1 (also known as AML1-ETO) encoding the AML1-ETO fusion protein. RUNX1-CBF2T1 positive-AML blasts had eight-fold lower CEBPA RNA levels and undetectable C/EBPalpha protein levels compared with other subgroups of AML patients. Conditional expression of RUNX1-CBF2T1 in U937 cells downregulated CEBPA mRNA, protein and DNA binding activity. AML1-ETO appears to suppress C/EBPalpha expression indirectly by inhibiting positive autoregulation of the CEBPA promoter. Conditional expression of C/EBPalpha in AML1-ETO-positive Kasumi-1 cells results in neutrophilic differentiation. We suggest that restoring C/EBPalpha expression will have therapeutic implications in RUNX1-CBF2T1-positive leukemias.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and abolishes C/EBP 𝛂 expression. 54”
From RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. (2003) · cites this paper as [54]
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“The U937T cell line in which U937 cells were stably transfected with the tetracycline transactivator (tTA) under the control of a tetracycline responsive elemen”
BackgroundEstablishment and characterization of a human histiocytic lymphoma cell line (U‐937)
Sundström, C., & Nilsson, K. (1976) · International Journal of Cancer · doi:10.1002/ijc.2910170504 · Cited by 2,407
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100
Luciferase reporter gene vectors for analysis of promoters and enhancers.
Nordeen, S. K. (1988) · PubMed · Cited by 994
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910
Self-citationPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901 · cited 1×
“a the abnormalities were one del (9)(q22;q34); one t(6;9); one t(10;21)(p11;q22); one 8;one 14; and one complex aberrant karyotype.”
BackgroundSelf-citationMiyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., & Ohki, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10431 · Cited by 872
Cited by
Items 201–300 of 462
Using cell fate attractors to uncover transcriptional regulation of HL60 neutrophil differentiation
Huang, A. C., Hu, L., Kauffman, S. A., Zhang, W., & Shmulevich, I. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-20 · Cited by 40
“Conditional expression of C/EBP leads to neutrophil differentiation while dominant-negative expressions of C/EBP are found in AML patients [63].”
BackgroundMyeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia
Braun, T. P., Okhovat, M., Coblentz, C., Carratt, S. A., Foley, A. C., Schonrock, Z., Curtiss, B. M., Nevonen, K. A., Davis, B. A., Garcia, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13364-2 · Cited by 38
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPα
Ferrari‐Amorotti, G., Keeshan, K., Zattoni, M., Guerzoni, C., Iotti, G., Cattelani, S., Donato, N. J., & Calabretta, B. (2006) · Blood · doi:10.1182/blood-2006-01-011833 · Cited by 38
Paz‐Priel, I., Ghosal, A., Kowalski, J., & Friedman, A. D. (2008) · Leukemia · doi:10.1038/leu.2008.297 · Cited by 40
Döhner, K., Tobis, K., Bischof, T., Hein, S., Schlenk, R. F., Fröhling, S., & Döhner, H. (2003) · Blood · doi:10.1182/blood-2003-08-2654 · Cited by 36
Heterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2003) · Blood · doi:10.1182/blood-2002-12-3903 · Cited by 37
Self-citationIL-1 in aging and pathologies of hematopoietic stem cells
Caiado, F., & Manz, M. G. (2024) · Blood · doi:10.1182/blood.2023023105 · Cited by 44
Soliera, A. R., Mariani, S. A., Audia, A., Lidonnici, M. R., Addya, S., Ferrari‐Amorotti, G., Cattelani, S., Manzotti, G., Fragliasso, V., Peterson, L. F., et al. (2012) · Leukemia · doi:10.1038/leu.2012.19 · Cited by 36
Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules
Janson, C. G., & During, M. J. (2006) · Springer eBooks · doi:10.1007/0-387-32956-0 · Cited by 41
C/EBPα redirects androgen receptor signaling through a unique bimodal interaction
Zhang, J., Gonit, M., Salazar, M. D., Shatnawi, A. A., Shemshedini, L., Trumbly, R. J., & Ratnam, M. (2009) · Oncogene · doi:10.1038/onc.2009.373 · Cited by 39
“C/EBPa also acts as a tumor suppressor (Watkins et al., 1996; Burel et al. 2001; Pabst et al., 2001a, b; Halmos et al., 2002; ; Gery et al., 2005; Schuster and Porse, 2006; Loomis et al., 2007).”
BackgroundZhi, L., Wang, M., Rao, Q., Fan, Y., Mi, Y., & Wang, J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.021 · Cited by 38
“AML1–ETO represses transcription of AML1 and blocks differentiation of hematopoietic stem and progenitor cells by the interaction between ETO and the human N-CoR/mSin3/HDAC1 complex [13–18].”
BackgroundMolecular mechanisms underlying deregulation of C/EBPα in acute myeloid leukemia
Reckzeh, K., & Cammenga, J. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0573-1 · Cited by 43
Asou, H., Gombart, A. F., Takeuchi, S., Tanaka, H., Tanioka, M., Matsui, H., Kimura, A., Inaba, T., & Koeffler, H. P. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10161 · Cited by 37
“In AML M2 with t(8; 21)(q22;q22), C/EBP -dependent activation of its own promoter was blocked by the AML1-ETO fusion protein, and expression of C/EBP protein was not detectable in t(8;21)-AML samples (Pabst et al., 2001b).”
BackgroundMethodInfluentialTranscriptional networks in acute myeloid leukemia
Thoms, J. A. I., Beck, D., & Pimanda, J. E. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22794 · Cited by 34
The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
Moser, B., Edtmayer, S., Witalisz‐Siepracka, A., & Stoiber, D. (2021) · Biomedicines · doi:10.3390/biomedicines9081051 · Cited by 40
“Similar sensitivity has been detected in AML cells expressing RUNX1–RUNX1T1 [98].”
BackgroundTran, H. T. T., Kim, H. N., Lee, I.-K., Nguyen-Pham, T.-N., Ahn, J., Kim, Y., Lee, J., Park, K.-S., Kook, H., & Kim, H. (2013) · Journal of Korean Medical Science · doi:10.3346/jkms.2013.28.2.237 · Cited by 36
“In addition, the AML1-ETO fusion acts to repress the transcription of key regulatory genes such as C/EBPα, which regulates the cell cycle control and myeloid differentiation (29).”
BackgroundShimada, H., Ichikawa, H., & Ohki, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402465 · Cited by 34
ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO
Lausen, J., Liu, S., Fliegauf, M., Lübbert, M., & Werner, M. H. (2005) · Oncogene · doi:10.1038/sj.onc.1209181 · Cited by 34
“AML1-ETO has also been implicated in suppressing expression of C/EBPa (Zhang et al., 1996; Petrovick et al., 1998; Westendorf et al., 1998; Pabst et al., 2001), which in turn could suppress expression of hELA2 in Kasumi-1 cells.”
BackgroundResultInfluentialDeregulated transcription factors in leukemia
Shima, Y., & Kitabayashi, I. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0905-9 · Cited by 36
Pioneer factors in development and cancer
Sunkel, B. D., & Stanton, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103132 · Cited by 33
“The AML-ETO chimeric fusion oncoprotein alters the function of CEBPa (Pabst et al., 2001; Vangala et al., 2003).”
BackgroundInfluentialRepression of Transcriptional Activity of C/EBPα by E2F-Dimerization Partner Complexes
Zaragoza, K., Bégay, V., Schuetz, A., Heinemann, U., & Leutz, A. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01619-09 · Cited by 38
“Abrogation of C/EBP functions has also been reported in AML-ETO and BCR-ABL leukemias (36, 38), and ectopic expression of C/EBP induces the differentiation of such leukemic cells (53, 54).”
BackgroundHug, B. A., Lee, S. Y. D., Kinsler, E. L., Zhang, J., & Lazar, M. A. (2002) · PubMed · Cited by 39
C/EBPα: critical at the origin of leukemic transformation
Roe, J., & Vakoc, C. R. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132530 · Cited by 35
The RUNX1/RUNX1T1 network: translating insights into therapeutic options
Swart, L. E., & Heidenreich, O. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.11.005 · Cited by 36
“In contrast, C/EBPa and RUNX1/RUNX1T1 form a negative feedback loop, with the latter directly interfering with the expression of the former [37,42].”
BackgroundDhawan, P., Weider, R., & Christakos, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803602200 · Cited by 35
Down-modulation of the C/EBPα transcription factor in core binding factor acute myeloid leukemias
Cilloni, D., Carturan, S., Gottardi, E. M., Messa, F., Messa, E., Fava, M., Diverio, D., Guerrasio, A., Lo‐Coco, F., & Saglio, G. N. (2003) · Blood · doi:10.1182/blood-2003-07-2256 · Cited by 33
Proteomic discovery of Max as a novel interacting partner of C/EBPα: a Myc/Max/Mad link
Zada, A. A., Pulikkan, J. A., Bararia, D., Geletu, M., Trivedi, A. K., Balkhi, M. Y., Hiddemann, W., Tenen, D. G., Behre, H. M., & Behre, G. (2006) · Leukemia · doi:10.1038/sj.leu.2404438 · Cited by 34
Self-citationTargeting oncogenic fusion genes in leukemias and lymphomas by RNA interference
Damm‐Welk, C., Fuchs, U., Wößmann, W., & Borkhardt, A. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(03)00042-7 · Cited by 30
Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML
Mulet‐Lazaro, R., van Herk, S., Erpelinck-Verschueren, C. A. J., Bindels, E. M., Sanders, M. A., Vermeulen, C., Renkens, I., Valk, P. J. M., Melnick, A. M., de Ridder, J., et al. (2021) · Blood · doi:10.1182/blood.2020009244 · Cited by 33
Zápotocký, M., Mejstříková, E., Smetana, K., Starý, J., Trka, J., & Starková, J. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.041 · Cited by 33
Zjablovskaja, P., Adamcova, M. K., Daněk, P., Angelisová, P., Benoukraf, T., Wurm, A. A., Kalina, T., Sian, S., Balaštík, M., Delwel, R., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.6 · Cited by 30
“It has also been shown that CEBPA can be downregulated by oncogenic fusion proteins such as AML1-ETO.(29) AML cases with these types of CEBPA alterations are included in the CEBPA WT group, and this could explain why some AML cases despite having WT CEBPA present very low EVI2B levels.”
BackgroundSelf-citationCammenga, J., Niebuhr, B., Horn, S., Bergholz, U., Putz, G., Buchholz, F., Löhler, J., & Stocking, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1903 · Cited by 32
Alterations of Lymphoid Enhancer Factor-1 Isoform Expression in Solid Tumors and Acute Leukemias
Wang, W., Ji, P., Steffen, B., Metzger, R., Schneider, P. M., Halfter, H., Schrader, M. G., Berdel, W. E., Serve, H. L., & Müller‐Tidow, C. (2005) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/37.3.173 · Cited by 29
Kandilci, A., & Grosveld, G. C. (2009) · Blood · doi:10.1182/blood-2009-02-205443 · Cited by 28
Gene Expression Profiles Associated with Pediatric Relapsed AML
Bachas, C., Schuurhuis, G. J., Zwaan, C. M., van den Heuvel‐Eibrink, M. M., den Boer, M. L., de Bont, E. S. J. M., Kwidama, Z. J., Reinhardt, D., Creutzig, U., de Haas, V., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121730 · Cited by 29
“been shown that the normal function of CEBPA in hematopoietic differentiation can be altered for example via oncogenic lesions [42], fusion proteins [43,44] or epigenetic alterations [45].”
BackgroundRUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT–enhancer binding protein α function
Tokita, K., Maki, K., & Mitani, K. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00597.x · Cited by 35
Lidonnici, M. R., Audia, A., Soliera, A. R., di Prisco, M., Ferrari‐Amorotti, G., Waldron, T. J., Donato, N. J., Zhang, Y., Martinez, R. V. P., Holyoake, T. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1667 · Cited by 36
C/EBPα Is Required for Proteolytic Cleavage of Cyclin A by Calpain 3 in Myeloid Precursor Cells
Welm, A. L., Timchenko, N. A., Ono, Y., Sorimachi, H., Radomska, H. S., Tenen, D. G., Lekstrom-Himes, J. A., & Darlington, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204096200 · Cited by 30
Self-citationBarbetti, V., Gozzini, A., Cheloni, G., Marzi, I., Fabiani, E., Santini, V., Sbarba, P. D., & Rovida, E. (2013) · Epigenetics · doi:10.4161/epi.23538 · Cited by 32
Matsushita, H., Nakajima, H., Nakamura, Y., Tsukamoto, H., Tanaka, Y., Gui-lan, J., Yabe, M., Asai, S., Ono, R., Nosaka, T., et al. (2008) · Oncogene · doi:10.1038/onc.2008.285 · Cited by 27
Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO
Berg, T., Fliegauf, M., Burger, J. A., Staege, M. S., Liu, S., Martinez, N., Heidenreich, O. T., Burdach, S. E. G., Haferlach, T., Werner, M. H., et al. (2008) · Haematologica · doi:10.3324/haematol.13044 · Cited by 27
Self-citationModeling the Hematopoietic Landscape
Brown, G., & Ceredig, R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00104 · Cited by 27
Zhuang, W., Cen, J., Zhao, Y., & Chen, Z. (2013) · Oncology Reports · doi:10.3892/or.2013.2459 · Cited by 28
Humbert, M., Federzoni, E. A., Britschgi, A., Schläfli, A. M., Valk, P. J. M., Kaufmann, T., Haferlach, T., Behre, G., Simon, H., Torbett, B. E., et al. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1112608 · Cited by 30
Self-citationMaun, N. A., Gaines, P. C. W., Khanna‐Gupta, A., Zibello, T., Enriquez, L., Goldberg, L., & Berliner, N. (2003) · Blood · doi:10.1182/blood-2002-10-3247 · Cited by 27
Insight into the molecular pathogenesis of myeloid malignancies
Haferlach, T., Bacher, U., Haferlach, C., Kern, W., & Schnittger, S. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3280168490 · Cited by 26
Self-citationRegulation of the C/EBPα signaling pathway in acute myeloid leukemia (Review)
Song, G., Wang, L., BI, K., & Jiang, G. (2015) · Oncology Reports · doi:10.3892/or.2015.3848 · Cited by 38
Sumoylation of hypoxia inducible factor-1α and its significance in cancer
Li, J., Xu, Y., Jiao, H., Wang, W., Mei, Z., & Chen, G. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4685-3 · Cited by 29
Liu, N., Song, J., Xie, Y., Wang, X.-L., Rong, B., Man, N., Zhang, M.-M., Zhang, Q., Gao, F.-F., Du, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809327116 · Cited by 25
RUNX3 regulates the activity of the CD11a and CD49d integrin gene promoters
Domínguez‐Soto, Á., Relloso, M., Vega, M. A., Corbí, A. L., & Puig‐Kröger, A. (2005) · Immunobiology · doi:10.1016/j.imbio.2005.05.008 · Cited by 30
Zhao, X., Liu, H., Wang, L., Yang, L., & Liu, X. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.010 · Cited by 25
Zhang, L., & Friedman, A. D. (2011) · Blood · doi:10.1182/blood-2011-01-331157 · Cited by 24
The challenge of risk stratification in acute myeloid leukemia with normal karyotype
Zaidi, S. Z. A., Owaidah, T. M., Sharif, F. A., Ahmed, S. Y., Chaudhri, N. A., & Aljurf, M. D. (2008) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/s1658-3876(08)50023-9 · Cited by 24
Lu, Y., Chen, W., Chen, W., Stein, A. S., Weiss, L. M., & Huang, Q. (2010) · American Journal of Hematology · doi:10.1002/ajh.21706 · Cited by 23
“Because of the important roles in leukemogenesis and powerful prognostic significance of C/EBPA gene mutation in CN-AML, the current WHO classification has adopted that de novo AML with mutated C/EBPA as one of distinct provisional entities in AML classification [1,9,10,11].”
BackgroundResultMarzac, C., Teyssandier, I., Calendini, O., Perrot, J., Faussat, A., Tang, R., Casadevall, N., Marie, J., & Legrand, O. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0641 · Cited by 23
Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia
Grossmann, V., Bacher, U., Kohlmann, A., Butschalowski, K., Roller, A., Jeromin, S., Dicker, F., Kern, W., Schnittger, S., Haferlach, T., et al. (2012) · Blood Cancer Journal · doi:10.1038/bcj.2012.34 · Cited by 21
Self-citationBuchi, F., Masala, E., Rossi, A., Valencia, A., Spinelli, E., Sanna, A., Gozzini, A., & Santini, V. (2013) · Epigenetics · doi:10.4161/epi.27322 · Cited by 25
Costa, D. B., Li, S., Kocher, O. N., Feins, R. H., Keller, S. M., Schiller, J. H., Johnson, D. H., Tenen, D. G., & Halmos, B. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.11.023 · Cited by 24
“The association of C/ EBPα and cancer has been elucidated in acute myeloid leukemia (AML) (19), where C/ EBPα expression is reduced in leukemias carrying the t(8;21) translocation (20) and C/ EBPα mutations confer improved prognosis in a small subgroup of AML patients with normal cytogenetics (21,22).”
BackgroundSelf-citationLRP16 is fused to RUNX1 in monocytic leukemia cell line with t(11;21)(q13;q22)
Imagama, S., Abe, A., Suzuki, M., Hayakawa, F., Katsumi, A., Emi, N., Kiyoi, H., & Naoe, T. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00858.x · Cited by 24
“was 46,XX, add(7)(q31),del(10)(q24),t(11;21)”
BackgroundMusialik‐Świetlińska, E., Bujko, M., Kober, P., Grygorowicz, M. A., Libura, M. A., Przestrzelska, M., Juszczyński, P., Borg, K., Florek, I., Jakóbczyk, M., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.04.013 · Cited by 23
Hypoxia-HIF-1α-C/EBPα/Runx1 signaling in leukemic cell differentiation
Zhang, J., & Chen, G. (2009) · Pathophysiology · doi:10.1016/j.pathophys.2009.02.005 · Cited by 22
Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription
Beghini, A. (2019) · Cancers · doi:10.3390/cancers11121973 · Cited by 25
“1, whose activity is altered by AML1-ETO [50,51].”
BackgroundTranscriptional and epigenetic regulation of the GM-CSF promoter by RUNX1
Taberlay, P. C., James, S. R., Qadi, A. A., West, A. C., Ray, S., Bert, A. G., Cockerill, P. N., & Holloway, A. F. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.03.029 · Cited by 26
Role of the RUNX1‐EVI1 fusion gene in leukemogenesis
Maki, K., Yamagata, T., & Mitani, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00956.x · Cited by 27
Hyde, R. K., & Liu, P. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22596 · Cited by 23
“In some instances, RUNX1 may be recruited to the promoters of target genes through protein–protein interactions with other transcription factors [Pabst et al., 2001; Wheeler et al., 2002].”
BackgroundYin, H., Radomska, H. S., Tenen, D. G., & Glass, J. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-158 · Cited by 24
“In other leukemias the fusion protein formed from the AML1-ETO translocation downregulates transcription of the C/EBPα gene [10].”
Self-citationFuchs, O. (2007) · Folia Biologica · doi:10.14712/fb2007053030097 · Cited by 36
Different mutant RUNX1 oncoproteins program alternate haematopoietic differentiation trajectories
Kellaway, S. G., Keane, P., Edginton‐White, B., Regha, K., Kennett, E., & Bonifer, C. (2021) · Life Science Alliance · doi:10.26508/lsa.202000864 · Cited by 17
“After hematopoietic stem cells (HSCs) have formed, its continued expression during differentiation is not essential but helps to correctly pattern and maintain cells in the correct lineage balance (Cai et al, 2011; Chen et al, 2009; Tober et al, 2013), in concert with other transcription factors such as the GATA, C/EB…”
BackgroundYin, H., Lowery, M. N., & Glass, J. (2009) · The Prostate · doi:10.1002/pros.20947 · Cited by 22
Yin, H., & Glass, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511138200 · Cited by 22
Fukuchi, Y., Ito, M., Shibata, F., Kitamura, T., & Nakajima, H. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0320 · Cited by 20
Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation
Rossetti, S., van Unen, L., Touw, I. P., Hoogeveen, A. T., & Sacchi, N. (2005) · Oncogene · doi:10.1038/sj.onc.1208651 · Cited by 22
Pharmacogenetics of Alkylator-Associated Acute Myeloid Leukemia
Knoche, E., McLeod, H. L., & Graubert, T. A. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.5.719 · Cited by 19
Hu, N., Zou, L., Wang, C., & Song, G. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03074-w · Cited by 24
“When the fusion protein binds with SMAD3, TGF/vitamin3-dependent myeloid differentiation is blocked [29].”
BackgroundManzotti, G., Parenti, S., Ferrari‐Amorotti, G., Soliera, A. R., Cattelani, S., Montanari, M., Cavalli, D., Ertel, A., Grande, A., & Calabretta, B. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1033591 · Cited by 25
“Expression of C/EBPa can be negatively regulated at the transcriptional level by promoter hypermethylation or by direct transcriptional repression by the AML1-ETO oncoprotein in AML patients with the 8;21 translocation.(9) C/EBPa is also inactivated post-transcriptionally by the mRNA-binding protein calreticulin that…”
BackgroundVries, I. S. N., Sackmann, Y., Klein, F., Ostareck‐Lederer, A., Ostareck, D. H., Jost, E., Ehninger, G., Brümmendorf, T. H., Marx, G., Röllig, C., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.11.007 · Cited by 19
MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR
Johnson, D. T., Davis, A. G., Zhou, J., Ball, E. D., & Zhang, D. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00204-7 · Cited by 21
Self-citationAML1/ETO–induced survivin expression inhibits transcriptional regulation of myeloid differentiation
Balkhi, M. Y., Christopeit, M., Chen, Y. X., Geletu, M., & Behre, G. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.05.008 · Cited by 21
“AML1/ETO dominantly inhibits C/ EBPa transcription and autoregulation of its own promotor [11,26–28].”
BackgroundSelf-citationEmetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells
Cornet-Masana, J. M., Moreno-Martínez, D., Lara-Castillo, M. C., Nomdedéu, M., Etxabe, A., Tesi, N., Pratcorona, M., Esteve, J., & Risueño, R. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8096 · Cited by 21
“As described previously [12], C/EBPα is inhibited by the fusion protein RUNX1/CBF2T1 that results in the block of granulocytic differentiation observed in this subtype of AML.”
BackgroundShimokawa, T., & Ra, C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2564 · Cited by 20
“Moreover, it has been shown that C/EBP is rapidly down-regulated during the monocytic differentiation and is undetectable in human peripheral blood monocytes, in contrast to the observation of its high level expression in blood neutrophils as well as its rapid up-regulation during granulocytic differentiation (30, 31).”
BackgroundSpecific protein redirection as a transcriptional therapy approach for t(8;21) leukemia
Steffen, B., Serve, H. L., Berdel, W. E., Agrawal, S., Linggi, B. E., Büchner, T., Hiebert, S. W., & Müller‐Tidow, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1330293100 · Cited by 19
Konopka, B., Szafron, L. M., Kwiatkowska, E., Podgórska, A., Zołocińska, A., Pieńkowska‐Grela, B., Dansonka‐Mieszkowska, A., Balcerak, A., Łukasik, M., Stachurska, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11822 · Cited by 18
Soliera, A. R., Lidonnici, M. R., Ferrari‐Amorotti, G., di Prisco, M., Zhang, Y., Martinez, R. V. P., Donato, N. J., & Calabretta, B. (2008) · Blood · doi:10.1182/blood-2007-09-114975 · Cited by 18
Claus, R., Fliegauf, M., Stock, M., Duque‐Afonso, J., Kolanczyk, M., & Lübbert, M. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0106005 · Cited by 23
“AML1/ETO is responsible for the specific phenotype of this leukemia type, by targeting multiple genes, several of which are transcriptionally repressed, such as the C/EBP- transcription factor [58] and the p14ARF cell cycle inhibitor [59].”
BackgroundPabst, T., Stillner, E., Neuberg, D. S., Nimer, S. D., Willman, C. L., List, A. F., Melo, J. V., Tenen, D. G., & Mueller, B. U. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06057.x · Cited by 17
Self-citationNew insight into the role of miRNAs in leukemia
Zhang, H., & Chen, Y. (2009) · Science in China Series C Life Sciences · doi:10.1007/s11427-009-0036-1 · Cited by 17
Loss of C/EBPα and Favorable Prognosis of Acute Myeloid Leukemias: A Biological Paradox
Perrotti, D., Marcucci, G., & Caligiuri, M. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.965 · Cited by 18
“In a recent study, Pabst et al [25] reported that suppression of neutrophilic differentiation in t(8;21)(q22;q22) FAB M2 AML appears to depend on inhibition of wild type CEBP transcription.”
BackgroundThe rate of spontaneous mutations in human myeloid cells
Araten, D. J., Krejci, O., DiTata, K., Wunderlich, M., Sanders, K. J., Zamechek, L. B., & Mulloy, J. C. (2013) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2013.05.004 · Cited by 19
Santana-Lemos, B. A. A., Lange, A. P., Benício, M. T. L., José, T., Lucena-Araujo, A. R., Krause, A., Thomé, C., & Rego, E. M. (2010) · Haematologica · doi:10.3324/haematol.2010.028365 · Cited by 17
“Pabst et al.(4) used a competitive quantitative reversetranscriptase (RT)-PCR assay, and Cilloni et al.”
MethodResultInfluentialLoke, J. C. T., Chin, P. S., Keane, P., Pickin, A., Assi, S. A., Ptasinska, A., Imperato, M. R., Cockerill, P. N., & Bonifer, C. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017012781 · Cited by 19
“t(3;21) SKH-1 cells were cultured in RPMI 1640 medium with 10% fetal calf serum (FCS).”
BackgroundMethodInfluentialC/EBPα mutations in lung cancer
Costa, D. B., Dayaram, T., D’Alò, F., Wouters, B. J., Tenen, D. G., Meyerson, M. M., Tsao, M., & Halmos, B. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.04.011 · Cited by 17
Self-citationLSD1 inhibition modulates transcription factor networks in myeloid malignancies
Hartung, E. E., Singh, K., & Berg, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1149754 · Cited by 19
Nucleic acid therapeutics as differentiation agents for myeloid leukemias
Kovecses, O., Mercier, F., & McKeague, M. (2024) · Leukemia · doi:10.1038/s41375-024-02191-0 · Cited by 23
“RUNX1::ETO is reported to act as a transcriptional repressor by recruiting histone deacetylases and DNA methyl transferases to tumour suppressor genes and critical myeloid transcription factors [40].”
BackgroundProtein‐Nanocaged Selenium Induces t(8;21) Leukemia Cell Differentiation via Epigenetic Regulation
Fang, L., Zhang, R., Shi, L., Xie, J., Ma, L., Yang, Y., Yan, X., & Fan, K. (2023) · Advanced Science · doi:10.1002/advs.202300698 · Cited by 14
GATA2 mutations in myeloid malignancies: Two zinc fingers in many pies
Leubolt, G., Monte, E. R., & Greif, P. A. (2019) · IUBMB Life · doi:10.1002/iub.2204 · Cited by 16
Stoner, S. A., Liu, K. T. H., Andrews, E. T., Liu, M., Arimoto, K., Yan, M., Davis, A. G., Weng, S., Dow, M. T., Su, X., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0282-9 · Cited by 17
Self-citationCDK2-instigates C/EBPα degradation through SKP2 in Acute myeloid leukemia
Thacker, G., Mishra, M., Sharma, A., Singh, A., Sanyal, S., & Trivedi, A. K. (2021) · Medical Oncology · doi:10.1007/s12032-021-01523-9 · Cited by 15
“Besides, C/EBPα mutations are also observed in 8–14% AML patients [9, 10].”
BackgroundMultiple ways of C/EBPα inhibition in myeloid leukaemia
Trivedi, A. K., Pal, P., Behre, G., & Singh, S. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.04.022 · Cited by 16
Self-citationQian, J., Chen, Z., Lin, J., Wang, W., & Cen, J. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.05.020 · Cited by 16
Behre, G., Reddy, V. A., Tenen, D. G., Hiddemann, W., Zada, A. A. P., & Singh, S. M. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.4.491 · Cited by 15
“Recent data from different laboratories indicate that interactions of transcription factors with other nuclear proteins plays not only an important role in lineage commitment and differentiation in the haematopoietic system but also in the pathogenesis of acute myeloid leukaemia (AML) [1-10].”
BackgroundSelf-citation
Metadata
- Authors
- Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.-E., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Helmholtz Munich (DE)
- Scripps Research Institute (US)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Medicine
- Published
- 2001-04
- Volume
- 7
- Issue
- 4
- Pages
- 444-451
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1489323849
- Semantic Scholar
- 0dc02b7bfde7f6d2b964fdb5715593ac0bec54f2
- Cited by
- 463
- References
- 45
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 8 · 2023: 12 · 2022: 4 · 2021: 16 · 2020: 8 · 2019: 13 · 2018: 9 · 2017: 14 · 2016: 10 · 2015: 13 · 2014: 7 · 2013: 18 · 2012: 18
- FWCI
- 15.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Keywords
- AML1-ETO, C/EBPα, CEBPA, acute myeloid leukemia, granulocytic differentiation, transcriptional repression, conditional gene expression, U937 cells, Kasumi-1 cells, therapeutic target
- MeSH terms
- RUNX1 Translocation Partner 1 Protein, Animals, Base Sequence, Cell Differentiation, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, DNA-Binding Proteins, Humans, Promoter Regions, Genetic, Proto-Oncogene Proteins, RNA, Messenger, RNA, Neoplasm, Transcription Factors, Translocation, Genetic, Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, Down-Regulation, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, Core Binding Factor Alpha 2 Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.